MIGRANAL

This brand name is authorized in Austria, Canada, United States, South Africa

Active ingredients

The drug MIGRANAL contains one active pharmaceutical ingredient (API):

1 Dihydroergotamine UNII 81AXN7R2QT - DIHYDROERGOTAMINE MESYLATE

Dihydroergotamine binds with high affinity to 5-HT1Dα and 5-HT1Dβ receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors. Read about Dihydroergotamine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MIGRANAL Nasal spray	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CA01	Dihydroergotamine	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CA Ergot alkaloids
Discover more medicines within N02CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02228947
Country: US	FDA, National Drug Code	Identifier(s): 0187-0245
Country: ZA	Health Products Regulatory Authority	Identifier(s): 33/7.3/0126